Pau Montesinos

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei, Pau Montesinos, Vladimir Ivanov et al. · Blood · 2020 · 756 citations · Full text

Medicine, Oncology, Pharmacology +9

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Jörge E. Cortes, Florian H. Heidel, Andrzej Hellmann et al. · Leukemia · 2018 · 489 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia

Pau Montesinos, Christian Récher, Susana Vives et al. · New England Journal of Medicine · 2022 · 483 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Jörge E. Cortes, Samer K. Khaled, Giovanni Martinelli et al. · The Lancet Oncology · 2019 · 479 citations

Medicine, Oncology, Pharmacology +11